{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:20:53Z","timestamp":1787656853054,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05042-2","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:21:18Z","timestamp":1770747678000},"page":"3781-3793","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessing the real-world safety of sparsentan for immunoglobulin A nephropathy: insights from a comprehensive analysis of FAERS database"],"prefix":"10.1007","volume":"58","author":[{"given":"Tailong","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenkai","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouqiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"5042_CR1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2215\/CJN.07420716","volume":"12","author":"JC Rodrigues","year":"2017","unstructured":"Rodrigues JC, Haas M, Reich HN (2017) IgA nephropathy. Clin J Am Soc Nephrol 12:677\u2013686. https:\/\/doi.org\/10.2215\/CJN.07420716","journal-title":"Clin J Am Soc Nephrol"},{"key":"5042_CR2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.01.024","author":"P Pattrapornpisut","year":"2021","unstructured":"Pattrapornpisut P, Avila-Casado C, Reich HN (2021) IgA nephropathy: core curriculum 2021. Am J Kidney Dis. https:\/\/doi.org\/10.1053\/j.ajkd.2021.01.024","journal-title":"Am J Kidney Dis"},{"key":"5042_CR3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","volume":"38","author":"FP Schena","year":"2018","unstructured":"Schena FP, Nistor I (2018) Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol 38:435\u2013442. https:\/\/doi.org\/10.1016\/j.semnephrol.2018.05.013","journal-title":"Semin Nephrol"},{"key":"5042_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.1","volume":"2","author":"KN Lai","year":"2016","unstructured":"Lai KN, Tang SCW, Schena FP et al (2016) IgA nephropathy. Nat Rev Dis Primers 2:16001. https:\/\/doi.org\/10.1038\/nrdp.2016.1","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"5042_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003962.pub3","volume":"2","author":"DJ Tunnicliffe","year":"2024","unstructured":"Tunnicliffe DJ, Reid S, Craig JC et al (2024) Non\u2010immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev 2(2):CD003962. https:\/\/doi.org\/10.1002\/14651858.CD003962.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"5042_CR6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00281-021-00888-3","volume":"43","author":"J Floege","year":"2021","unstructured":"Floege J, Rauen T, Tang SCW (2021) Current treatment of IgA nephropathy. Semin Immunopathol 43:717\u2013728. https:\/\/doi.org\/10.1007\/s00281-021-00888-3","journal-title":"Semin Immunopathol"},{"key":"5042_CR7","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2017.9362","volume":"318","author":"J Lv","year":"2017","unstructured":"Lv J, Zhang H, Wong MG et al (2017) Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 318:432\u2013442. https:\/\/doi.org\/10.1001\/jama.2017.9362","journal-title":"JAMA"},{"key":"5042_CR8","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJMc1600141","volume":"374","author":"T Robert","year":"2016","unstructured":"Robert T, Cambier A, Hertig A (2016) Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 374:991. https:\/\/doi.org\/10.1056\/NEJMc1600141","journal-title":"N Engl J Med"},{"key":"5042_CR9","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.ekir.2023.02.1086","volume":"8","author":"J Barratt","year":"2023","unstructured":"Barratt J, Rovin B, Wong MG et al (2023) IgA Nephropathy patient baseline characteristics in the Sparsentan PROTECT study. Kidney Int Rep 8:1043. https:\/\/doi.org\/10.1016\/j.ekir.2023.02.1086","journal-title":"Kidney Int Rep"},{"key":"5042_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1358\/dof.2020.45.2.3058863","volume":"45","author":"H Trachtman","year":"2020","unstructured":"Trachtman H, Hogan JJ, Tesar V, Komers R (2020) Sparsentan. Dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist, treatment of focal segmental glomerulosclerosis, treatment of IgA nephropathy. Drugs Future 45:79. https:\/\/doi.org\/10.1358\/dof.2020.45.2.3058863","journal-title":"Drugs Future"},{"key":"5042_CR11","doi-asserted-by":"publisher","first-page":"R877","DOI":"10.1152\/ajpregu.00425.2015","volume":"310","author":"R Komers","year":"2016","unstructured":"Komers R, Plotkin H (2016) Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease. Am J Physiol Regul Integr Comp Physiol 310:R877-884. https:\/\/doi.org\/10.1152\/ajpregu.00425.2015","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"5042_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1681\/ASN.20213210S1459a","volume":"32","author":"C Reily","year":"2021","unstructured":"Reily C, Moldoveanu Z, Pramparo T et al (2021) The dual endothelin angiotensin receptor antagonist (DEARA) sparsentan protects from glomerular hypercellularity and associated immune\/inflammatory gene network activity in a model of IgA nephropathy: PO1454. J Am Soc Nephrol 32:459. https:\/\/doi.org\/10.1681\/ASN.20213210S1459a","journal-title":"J Am Soc Nephrol"},{"key":"5042_CR13","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","volume":"401","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink HJL, Radhakrishnan J, Alpers CE et al (2023) Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet 401:1584\u20131594. https:\/\/doi.org\/10.1016\/S0140-6736(23)00569-X","journal-title":"Lancet"},{"key":"5042_CR14","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","volume":"402","author":"BH Rovin","year":"2023","unstructured":"Rovin BH, Barratt J, Heerspink HJL et al (2023) Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet 402:2077\u20132090. https:\/\/doi.org\/10.1016\/S0140-6736(23)02302-4","journal-title":"Lancet"},{"key":"5042_CR15","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1080\/1744666X.2024.2319132","volume":"20","author":"H Trachtman","year":"2024","unstructured":"Trachtman H, Komers R, Inrig J (2024) Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy. Expert Rev Clin Immunol 20:571\u2013576. https:\/\/doi.org\/10.1080\/1744666X.2024.2319132","journal-title":"Expert Rev Clin Immunol"},{"key":"5042_CR16","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s40265-023-01864-x","volume":"83","author":"YY Syed","year":"2023","unstructured":"Syed YY (2023) Sparsentan: first approval. Drugs 83:563\u2013568. https:\/\/doi.org\/10.1007\/s40265-023-01864-x","journal-title":"Drugs"},{"key":"5042_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1443555","volume":"15","author":"W Li","year":"2024","unstructured":"Li W, Liu C, Zhang Z et al (2024) Exploring the top 30 drugs associated with drug-induced constipation based on the FDA adverse event reporting system. Front Pharmacol 15:1443555. https:\/\/doi.org\/10.3389\/fphar.2024.1443555","journal-title":"Front Pharmacol"},{"key":"5042_CR18","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y (2013) Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci 10:796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048","journal-title":"Int J Med Sci"},{"key":"5042_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/00002018-200730050-00001","volume":"30","author":"WN Kelly","year":"2007","unstructured":"Kelly WN, Arellano FM, Barnes J et al (2007) Guidelines for submitting adverse event reports for publication. Drug Saf 30:367\u2013373. https:\/\/doi.org\/10.2165\/00002018-200730050-00001","journal-title":"Drug Saf"},{"key":"5042_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR et al (1998) A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54:315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466","journal-title":"Eur J Clin Pharmacol"},{"key":"5042_CR21","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1592\/phco.24.13.1099.38090","volume":"24","author":"A Szarfman","year":"2004","unstructured":"Szarfman A, Tonning JM, Doraiswamy PM (2004) Pharmacovigilance in the 21st century: new systematic tools for an old problem. Pharmacotherapy 24:1099\u20131104. https:\/\/doi.org\/10.1592\/phco.24.13.1099.38090","journal-title":"Pharmacotherapy"},{"key":"5042_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-024-03713-9","volume":"25","author":"AAA Elnaga","year":"2024","unstructured":"Elnaga AAA, Alsaied MA, Elettreby AM et al (2024) Safety and efficacy of sparsentan versus irbesartan in focal segmental glomerulosclerosis and IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials. BMC Nephrol 25:316. https:\/\/doi.org\/10.1186\/s12882-024-03713-9","journal-title":"BMC Nephrol"},{"key":"5042_CR23","doi-asserted-by":"publisher","first-page":"2465810","DOI":"10.1080\/0886022X.2025.2465810","volume":"47","author":"X Ma","year":"2025","unstructured":"Ma X, Liang Y, Chen W et al (2025) The role of endothelin receptor antagonists in kidney disease. Ren Fail 47:2465810. https:\/\/doi.org\/10.1080\/0886022X.2025.2465810","journal-title":"Ren Fail"},{"key":"5042_CR24","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.amjhyper.2004.11.032","volume":"18","author":"RE Schmieder","year":"2005","unstructured":"Schmieder RE (2005) Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am J Hypertens 18:720\u2013730. https:\/\/doi.org\/10.1016\/j.amjhyper.2004.11.032","journal-title":"Am J Hypertens"},{"key":"5042_CR25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3949\/ccjm.86a.18024","volume":"86","author":"T Momoniat","year":"2019","unstructured":"Momoniat T, Ilyas D, Bhandari S (2019) ACE inhibitors and ARBs: managing potassium and renal function. Cleve Clin J Med 86:601\u2013607. https:\/\/doi.org\/10.3949\/ccjm.86a.18024","journal-title":"Cleve Clin J Med"},{"key":"5042_CR26","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40264-014-0196-1","volume":"37","author":"C Ben Salem","year":"2014","unstructured":"Ben Salem C, Badreddine A, Fathallah N et al (2014) Drug-induced hyperkalemia. Drug Saf 37:677\u2013692. https:\/\/doi.org\/10.1007\/s40264-014-0196-1","journal-title":"Drug Saf"},{"key":"5042_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1161\/01.hyp.35.1.155","volume":"35","author":"RM Carey","year":"2000","unstructured":"Carey RM, Wang ZQ, Siragy HM (2000) Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 35:155\u2013163. https:\/\/doi.org\/10.1161\/01.hyp.35.1.155","journal-title":"Hypertension"},{"key":"5042_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physrev.00060.2009","volume":"91","author":"DE Kohan","year":"2011","unstructured":"Kohan DE, Rossi NF, Inscho EW, Pollock DM (2011) Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 91:1\u201377. https:\/\/doi.org\/10.1152\/physrev.00060.2009","journal-title":"Physiol Rev"},{"key":"5042_CR29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2147\/IJNRD.S430377","volume":"16","author":"KN Campbell","year":"2023","unstructured":"Campbell KN, Griffin S, Trachtman H et al (2023) Practical considerations for the use of sparsentan in the treatment of patients with IgAN in clinical practice. Int J Nephrol Renovasc Dis 16:281\u2013291. https:\/\/doi.org\/10.2147\/IJNRD.S430377","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"5042_CR30","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/147616","volume":"2015","author":"T Elisa","year":"2015","unstructured":"Elisa T, Antonio P, Giuseppe P et al (2015) Endothelin receptors expressed by immune cells are involved in modulation of inflammation and in fibrosis: relevance to the pathogenesis of systemic sclerosis. J Immunol Res 2015:147616. https:\/\/doi.org\/10.1155\/2015\/147616","journal-title":"J Immunol Res"},{"key":"5042_CR31","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1161\/HYPERTENSIONAHA.119.12105","volume":"74","author":"M Barton","year":"2019","unstructured":"Barton M, Yanagisawa M (2019) Endothelin: 30 years from discovery to therapy. Hypertension 74:1232\u20131265. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.12105","journal-title":"Hypertension"},{"key":"5042_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-018-0848-0","volume":"20","author":"M Burnier","year":"2018","unstructured":"Burnier M (2018) Update on endothelin receptor antagonists in hypertension. Curr Hypertens Rep 20:51. https:\/\/doi.org\/10.1007\/s11906-018-0848-0","journal-title":"Curr Hypertens Rep"},{"key":"5042_CR33","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1161\/CIRCRESAHA.116.303587","volume":"116","author":"L Te Riet","year":"2015","unstructured":"Te Riet L, van Esch JHM, Roks AJM et al (2015) Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res 116:960\u2013975. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.303587","journal-title":"Circ Res"},{"key":"5042_CR34","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s13105-016-0514-4","volume":"72","author":"Z Miloradovi\u0107","year":"2016","unstructured":"Miloradovi\u0107 Z, Ivanov M, Jovovi\u0107 \u0110 et al (2016) Angiotensin 2 type 1 receptor blockade different affects postishemic kidney injury in normotensive and hypertensive rats. J Physiol Biochem 72:813\u2013820. https:\/\/doi.org\/10.1007\/s13105-016-0514-4","journal-title":"J Physiol Biochem"},{"key":"5042_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nrneph.2010.175","volume":"7","author":"RJ Unwin","year":"2011","unstructured":"Unwin RJ, Luft FC, Shirley DG (2011) Pathophysiology and management of hypokalemia: a clinical perspective. Nat Rev Nephrol 7:75\u201384. https:\/\/doi.org\/10.1038\/nrneph.2010.175","journal-title":"Nat Rev Nephrol"},{"key":"5042_CR36","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/psp4.13086","volume":"13","author":"NK Patel","year":"2024","unstructured":"Patel NK, Chen K-F, Chen S-C, Liu K (2024) Physiologically-based pharmacokinetic model of sparsentan to evaluate drug-drug interaction potential. CPT Pharmacometrics Syst Pharmacol 13:317\u2013329. https:\/\/doi.org\/10.1002\/psp4.13086","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"5042_CR37","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1053\/jhep.2003.50393","volume":"38","author":"R Wolbold","year":"2003","unstructured":"Wolbold R, Klein K, Burk O et al (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38:978\u2013988. https:\/\/doi.org\/10.1053\/jhep.2003.50393","journal-title":"Hepatology"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05042-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05042-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05042-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:40:21Z","timestamp":1787654421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05042-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["5042"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05042-2","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}